Properties of Memantine and Mechanism of Action

19
Properties of Memantine and Mechanism of Action

description

Properties of Memantine and Mechanism of Action. Structural Formula of Memantine. NH 3 +. CH 3. H 3 C. 1-amino-3,5-dimethyl-adamantane. Memantine is a NMDA Receptor Channel Antagonist. (³H)-MK-801 binding to homogenates of postmortem human cortex. 100 80 60 40 20 0. - PowerPoint PPT Presentation

Transcript of Properties of Memantine and Mechanism of Action

Page 1: Properties of Memantine and Mechanism of Action

Properties of Memantineand Mechanism of Action

Page 2: Properties of Memantine and Mechanism of Action

NH3+

CH3

H3C

1-amino-3,5-dimethyl-adamantane

Structural Formula of Memantine

Page 3: Properties of Memantine and Mechanism of Action

Kornhuber et al., Eur J Pharmacol 1989

(³H)-MK-801 binding to homogenates of postmortem human cortex

Spe

cific

(3 H

)-M

K-8

01 B

indi

ng (

%)

10.01 0.1 10 100

100

80

60

40

20

0

Memantine is a NMDA Receptor Channel Antagonist

Concentration (µM)

Memantine Ki = 0.54 ± 0.04 µM

MK-801 Ki = 0.0012 ± 0.00015 µM

Page 4: Properties of Memantine and Mechanism of Action

Kinetics of NMDA-Receptor Blockade Intermediate between Mg2+ and MK-801

Mg2+ shows very fast blockade of NMDA receptors and also fast unblockade

MK-801

(+)MK-801 shows very slow blockade of NMDA receptorsand also slow unblockadeMemantine shows fast blockade of NMDA receptors

MemantineMg2+

Peaks represent responses to

application of NMDA

time

and also relatively fast unblockade

Parsons et al., Neuropharmacology 1993

Page 5: Properties of Memantine and Mechanism of Action

Parsons et al., Neuropharmacology 1993

Con

trol

Res

pons

e (%

)

100

80

60

40

20

0

The voltage-dependency of memantine is intermediate between that of Mg2+ and MK-801

restingcondition

pathological activation

physiological synaptic transmisson

Memantine

Mg2+

MK-801

Increasing membrane potential

Moderate Voltage-Dependency of Memantine

Page 6: Properties of Memantine and Mechanism of Action

Memantine

MK-801, PCP

Magnesium

Resting Condition(- 70mV)

PathologicalCondition(- 50mV)

Physiological synapticNeurotransmission

(- 20mV)

Parsons et al., Neuropharmacolgy 1999 (mod. from Kornhuber)

Ca2+ Ca2+

Ca2+

Properties of Memantine

Page 7: Properties of Memantine and Mechanism of Action

Normal Situation

AXURA: Mechanism of Action

Presynaptic:Neuronal signal

• Recycling of glutamate in glia cell

Postsynaptic:Detected signal

GLUTAMATE

• Glutamate transmits signal via the NMDA receptor

Page 8: Properties of Memantine and Mechanism of Action

Alzheimer’s Disease

AXURA: Mechanism of Action

GLUTAMATE

Presynaptic:Neuronal signal

Postsynaptic:Inhibited signal detection• Excess glutamate masks signal

transmission

ß-Amyloid

• ß-Amyloid inhibits glutamate recycling

Page 9: Properties of Memantine and Mechanism of Action

AXURA Treatment

AXURA: Mechanism of Action

GLUTAMATE

Presynaptic:Neuronal signal

• Restoration of physiological signal transmission

Postsynaptic:Stabilized signal detection

ß-Amyloid

• AXURA blocks effect of excess glutamate

Page 10: Properties of Memantine and Mechanism of Action

Normal Situation

Memantine: Mechanism of Action

Presynaptic:Neuronal signal

• Recycling of glutamate in glia cell

Postsynaptic:Detected signal

GLUTAMATE

• Glutamate transmits signal via the NMDA receptor

Page 11: Properties of Memantine and Mechanism of Action

Alzheimer’s Disease

Memantine: Mechanism of Action

GLUTAMATE

Presynaptic:Neuronal signal

Postsynaptic:Inhibited signal detection• Excess glutamate masks signal

transmission

ß-Amyloid

• ß-Amyloid inhibits glutamate recycling

Page 12: Properties of Memantine and Mechanism of Action

Memantine Treatment

Memantine: Mechanism of Action

GLUTAMATE

Presynaptic:Neuronal signal

• Restoration of physiological signal transmission

Postsynaptic:Stabilized signal detection

ß-Amyloid

• Memantine blocks effect excess glutamate

Memantine

Page 13: Properties of Memantine and Mechanism of Action

Normal Situation

AXURA: Mechanism of Action

GLUTAMATE

Glutamate as signal transmitter Postsynaptic:Detected signal

Presynaptic:Neuronal signal

Page 14: Properties of Memantine and Mechanism of Action

Alzheimer’s Disease

AXURA: Mechanism of Action

GLUTAMATE

Excess glutamate masks signaltransmission

Excess glutamate

Postsynaptic:Inhibited signal detection

Presynaptic:Neuronal signal

Page 15: Properties of Memantine and Mechanism of Action

AXURA Treatment

AXURA: Mechanism of Action

Postsynaptic:Stabilized signaldetection

Presynaptic:Neuronal signal

Excess glutamate

Excess glutamate

GLUTAMATE

• AXURA blocks effect of excess glutamate

• Restoration of physiological signal transmission

Page 16: Properties of Memantine and Mechanism of Action

Normal Situation

Memantine: Mechanism of Action

GLUTAMATE

Glutamate as signal transmitter Postsynaptic:Detected signal

Presynaptic:Neuronal signal

Page 17: Properties of Memantine and Mechanism of Action

Alzheimer’s Disease

Memantine: Mechanism of Action

GLUTAMATE

Excess glutamate masks signaltransmission

Excess glutamate

Postsynaptic:Inhibited signal detection

Presynaptic:Neuronal signal

Page 18: Properties of Memantine and Mechanism of Action

Memantine Treatment

Memantine: Mechanism of Action

Postsynaptic:Stabilized signaldetection

Presynaptic:Neuronal signal

Excess glutamate

GLUTAMATE

Excess glutamate

• Restoration of physiological signal transmission

• Memantine blocks effect of excess glutamate

Memantine

Page 19: Properties of Memantine and Mechanism of Action

Memantine Treatment Can not Be Replaced by Magnesium

Pharmacokinetic reasons:

• Mg2+: poorly absorbed from GI tract (Fawcett et al., 1999)

• Mg2+: hardly passes blood-brain barrier (Hallak, 1998)

High parenteral dosages required which may lead to life-threatening adverse events due to hypermagnesemia (reviewed by Fung et al., 1995)

Pharmacodynamic reasons:

• Due to higher voltage dependency Mg2+ is expected to have less capacity to block sustained background noise

• Potential interaction of Mg2+ with central cholinergic system may lead to impairment of cholinergic neurotransmission (Fung et al., 1995; Ladner and Lee, 1999)

Worsening of cholinergic deficit in AD patients